Comportamento reprodutivo de Synthesiomyia nudiseta van der Wulp (Diptera: Muscidae) sob condições de laboratório

Observations were carried out on the reproductive behavior of Synthesiomyia nudiseta females. The results of the biological parameters were: pre-oviposition period (15.5 ± 4.7 days), oviposition period (25.4 ± 14.7 days), number of eggs per oviposition (95.9 ± 18.4) rate of ovipositant females (97.5%), number of ovipositions (5.31 ± 3.2), number of eggs per females (509.7 ± 324.9), rate of hatching (68.0 ± 19.0), female longevity (53.2 ± 14.7 days), reproductive potential (67.4%) and reproductive investiment (4.1).

L'Académie de Lausanne entre Humanisme et Réforme (ca. 1537-1560)

L'Académie de Lausanne est la première école supérieure protestante implantée en territoire francophone. Lausanne constitue ainsi, dès les années 1540, un pôle de première importance dans le monde réformé. De nombreux savants protestants, attirés par la liberté de pratiquer leur foi et par la présence de l'Académie, s'établissent dans cette ville et des étudiants affluent de toute l'Europe. Les structures de l'Académie de Lausanne et son programme d'enseignement, fixés par un règlement daté de 1547, condensent sous une forme nouvelle les réflexions pédagogiques de la Renaissance. Ils constituent un modèle, direct ou indirect, pour toutes les Académies calvinistes fondées aux XVIème et XVIIème siècles, que ce soit à Genève, en France, en Allemagne, aux Pays-Bas, en Écosse, en Pologne ou encore aux États-Unis, dont les trois premiers Colleges, Harvard, William and Mary et Yale, se situent dans la même tradition. Malgré la place fondamentale qu'occupe l'Académie de Lausanne dans l'histoire de l'éducation protestante, la phase de création et de développement de cette institution était encore très mal connue. Cette thèse comble cette lacune de l'historiographie par la mise au jour et par l'analyse de nombreux documents, en grande partie inédits. Elle détruit bon nombre de préjugés entourant la mise en place et les buts de l'Académie de Lausanne à ses débuts. Ainsi, l'Académie de Lausanne n'est pas uniquement une école de pasteurs, comme il a souvent été affirmé jusqu'à ce jour, mais plus largement une institution offrant une formation d'un niveau très élevé dans les trois langues anciennes, (latin, grec et hébreu), en arts libéraux, en philosophie naturelle et morale, et en théologie. Au milieu du XVIème siècle, l'Académie lausannoise est capable de rivaliser avec les meilleures institutions pédagogiques de la Renaissance et d'attirer, dans un rayon très large, non seulement des étudiants qui se destinent au pastorat, mais aussi ceux qui sont formés pour gouverner leurs cités. Plus généralement, cette thèse, qui combine des approches d'histoire intellectuelle, d'histoire politique et d'histoire sociale, reconstitue et analyse les structures de l'Académie de Lausanne jusqu'à 1560, ainsi que ses fonctions éducatives, confessionnelles et politiques.

Mapping HIV-related behavioural surveillance among injecting drug users in Europe, 2008.

The systematic collection of behavioural information is an important component of second-generation HIV surveillance. The extent of behavioural surveillance among injecting drug users (IDUs) in Europe was examined using data collected through a questionnaire sent to all 31 countries of the European Union and European Free Trade Association as part of a European-wide behavioural surveillance mapping study on HIV and other sexually transmitted infections. The questionnaire was returned by 28 countries during August to September 2008: 16 reported behavioural surveillance studies (two provided no further details). A total of 12 countries used repeated surveys for behavioural surveillance and five used their Treatment Demand Indicator system (three used both approaches). The data collected focused on drug use, injecting practices, testing for HIV and hepatitis C virus and access to healthcare. Eight countries had set national indicators: three indicators were each reported by five countries: the sharing any injecting equipment, uptake of HIV testing and uptake of hepatitis C virus testing. The recall periods used varied. Seven countries reported conducting one-off behavioural surveys (in one country without a repeated survey, these resulted an informal surveillance structure). All countries used convenience sampling, with service-based recruitment being the most common approach. Four countries had used respondent-driven sampling. Three fifths of the countries responding (18/28) reported behavioural surveillance activities among IDUs; however, harmonisation of behavioural surveillance indicators is needed.

La Inspiració de Van Gogh

La Inspiració de Van Gogh ofereix una reflexió entre les similituds i coincidències de dues societats (la societat de finals del sXIX, i la societat actual) separades pel temps, però unides per la necessitat de trobar una sortida a tanta incomprensió artística i social.

Identification and molecular characterization of Van A-type vancomycin-resistant Enterococcus faecalis in Northeast of Brazil

The isolation of vancomycin resistant enterococci (VRE) in Brazil has rapidly increased, following the world wide tendency. We report in the present study the first isolation of vancomycin resistant Enterococcus faecalis (VRE) in the Northeast of Brazil. The four VRE isolates were characterized for antimicrobial susceptibility, genotypic typing by macro restriction of chromosomal DNA followed by pulsed-field gel electrophoresis and for characterization of the Tn1546-like element and plasmid contents. The isolates showed resistance to multiple antibiotics and a single genotype profile, suggesting the dissemination of a single clone among the patients. Tn1546 associated to genetic elements as plasmids shows the importance of infection control measures to avoid the spreading of glycopetide resistance by conjugative transfer of VanA elements.

Y-90 Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced Stage Follicular Non Hodgkin's Lymphoma Updated Results After a Median Follow up of 662 Months From the International, Randomized, Phase III First Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Long-term follow-up of follicular lymphoma (FL) patients receiving single agent rituximab at two different schedules in trial SAKK 35/98

Background: In FL, Rituximab as a single agent delivered in the standard schedule (4 times weekly) may induce a response rate of 50−70% with an event-free survival (EFS) of 1−3 years according to patients' characteristics. Prolonged Rituximab exposure seems to improve EFS at least in responding patients and to increase the rate of longterm responders. Here we report long-term results of a clinical trial comparing single agent Rituximab delivered in the standard schedule versus prolonged exposure, with focus on the proportion of long-term responders and their characteristics. Material and Methods: Between 1998 and 2002, chemotherapy na¨ıve (n = 64) or pre-treated (n = 138) FL patients received Rituximab in the standard schedule. Those responding or with stable disease were randomized to no further treatment (observation, n = 78) or 4 additional doses of Rituximab given at 2-month intervals (prolonged exposure, n = 73). EFS was calculated from the first dose of standard schedule until progression, relapse, second tumor or death. Results: At a median follow up of 9.4 years and with all living patients having been followed for at least 5 years, the median EFS is 13 months for the observation and 24 months for the prolonged exposure arm (p = 0.0007). In the observation arm 13% had no event at 5-years and only 4% at 8 years, while in the prolonged exposure arm it was 27% at 5 years and remained 21% at 8 years. The only significant prognostic factor for EFS in a multivariate Cox regression was the prolonged Rituximab schedule (hazard ratio 0.58, CI 0.39−0.86, p = 0.007), whereas being chemotherapy na¨ıve, presenting with stage

Rabid puppy-dog imported into the Netherlands from Morocco via Spain, February 2012.

To the editor: We read with interest the article by van Rijckevorsel et al. on a rabid puppy-dog imported into the Netherlands from Morocco via Spain, recently published in Eurosurveillance [1]. We would like to complete the information on this event with actions taken by the Spanish health authorities and lessons learnt.

4-7-19, stade Pershing, arrivée du marathon [modifié des Jeux interalliés, Jean Vermeulen coupe la ligne d'arrivée, le n°971 Armando Pagliani et le n°1280 Alphonse Van Hoey sont distancés] : [photographie de presse] / [Agence Rol]

Référence bibliographique : Rol, 54715